Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yohann Loriot

Showing results (1-10 of 275) with videos related to

Pageof 28
Sort By:
European Urology Focus|October 18, 2024
Treatments for Patients with Metastatic Castration-resistant Prostate Cancer Who Previously Received Triplet Therapy at the Metastatic Hormone-sensitive StageYohann Loriot, Karim Fizazi
Bulletin Du Cancer|May 31, 2007
[Management of clinical stage I testicular germ cell tumours]Yohann Loriot, Karim Fizazi
La Revue Du Praticien|April 26, 2007
[Management of localized germ-cell tumours of the testis]Yohann Loriot, Karim Fizazi
European Urology Oncology|February 6, 2025
Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti's Letter to the Editor re: Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 2024;7:1051-60Bertrand Tombal, Yohann Loriot
European Urology|October 1, 2013
Towards random sequencing or precision medicine in castration-resistant prostate cancer?Yohann Loriot, Karim Fizazi
Bulletin Du Cancer|July 5, 2020
[Immunotherapies in non-muscle invasive bladder cancer: immunotherapies and NMIBC]Yohann Loriot, Morgan Rouprêt
European Urology|August 29, 2020
The FGFR3 Story in Bladder Cancer: Another Piece of the Puzzle?Ronan Flippot, Yohann Loriot
European Urology|February 12, 2013
Taxanes: still a major weapon in the armamentarium against prostate cancerYohann Loriot, Karim Fizazi
Hematology/Oncology Clinics of North America|May 7, 2021
Emerging Targeted Therapy for Bladder CancerConstance Thibault, Yohann Loriot
European Urology|October 7, 2023
Towards Tailored Adjuvant Therapy in Bladder Urothelial Carcinoma: How Should We Fit Each Size?Natacha Naoun, Yohann Loriot
Pageof 28

Showing results (1-10 of 275) with videos related to

Sort By:
Pageof 28
European Urology Focus|October 18, 2024
Treatments for Patients with Metastatic Castration-resistant Prostate Cancer Who Previously Received Triplet Therapy at the Metastatic Hormone-sensitive StageYohann Loriot, Karim Fizazi
Bulletin Du Cancer|May 31, 2007
[Management of clinical stage I testicular germ cell tumours]Yohann Loriot, Karim Fizazi
La Revue Du Praticien|April 26, 2007
[Management of localized germ-cell tumours of the testis]Yohann Loriot, Karim Fizazi
European Urology Oncology|February 6, 2025
Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti's Letter to the Editor re: Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 2024;7:1051-60Bertrand Tombal, Yohann Loriot
European Urology|October 1, 2013
Towards random sequencing or precision medicine in castration-resistant prostate cancer?Yohann Loriot, Karim Fizazi
Bulletin Du Cancer|July 5, 2020
[Immunotherapies in non-muscle invasive bladder cancer: immunotherapies and NMIBC]Yohann Loriot, Morgan Rouprêt
European Urology|August 29, 2020
The FGFR3 Story in Bladder Cancer: Another Piece of the Puzzle?Ronan Flippot, Yohann Loriot
European Urology|February 12, 2013
Taxanes: still a major weapon in the armamentarium against prostate cancerYohann Loriot, Karim Fizazi
Hematology/Oncology Clinics of North America|May 7, 2021
Emerging Targeted Therapy for Bladder CancerConstance Thibault, Yohann Loriot
European Urology|October 7, 2023
Towards Tailored Adjuvant Therapy in Bladder Urothelial Carcinoma: How Should We Fit Each Size?Natacha Naoun, Yohann Loriot
Pageof 28